By Kimberley Donoghue PBN Web Editor Twitter: @kdonog
PROVIDENCE – Isis Biopolymer appointed Chris Hobson as the new president and CEO as of Oct. 1.
Isis – which has combined miniaturization and microcomputing with advanced life-science knowledge to produce a noninvasive treatment for facial wrinkles that promises efficacy at a much lower price than more aggressive approaches, such as Botox – also appointed Hobson to its board of directors.
The company recently launched its Biobliss anti-aging line of skin-care products.
Hobson brings more than 18 years of experience leading early-stage ventures, raising capital and developing successful business models, the company said in a news release on Oct. 12.
“I am extremely excited to join the Isis Biopolymer team,” said Hobson. “Isis combines all of the key criteria that I was looking for in my next venture: break-through technology and intellectual property that is poised to disrupt a huge market; an excellent team; and sophisticated, value-added investors.”
Hobson served as chief operating officer of TxtEagle, a mobile research and advertising startup; in 2009, he co-founded Bandgap Engineering, developing high-efficiency solar cells based on nano-structured silicon. He began his career at Proctor & Gamble in the Beauty Care division. He earned his bachelor’s degree at McGill University and his MBA at Harvard Business School.
Hobson replaces David Poor, chairman of the board, who served as the interim CEO since October 2010 when Emma A. Durand, co-CEO and Chief Technology Officer, passed away.
noninvasive treatment for facial wrinkles,
skin care products,
Emma A. Durand